News
Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
NEW YORK, April 16, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its....
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
NEW YORK, April 10, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing....
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is....
Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
NEW YORK, March 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results
Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
SP-333 Advances to Multiple-Dosing Safety Study
NEW YORK, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders,
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
NEW YORK, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously
Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ("Synergy") today announced that it convened its annual meeting of stockholders yesterday and it has received
BG Medicine annonce l'obtention de la marque CE et le lancement de la version automatisée du test BGM de la Galectine-3
Introduction du premier test automatisé en Europe et dans les territoires reconnaissant la marque CE
WALTHAM, Massachussetts, 4 janvier 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation
Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints
NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its
BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test
First Automated Test Launches in Europe and Territories Recognizing the CE Mark
WALTHAM, Mass., Jan. 3, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development
Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases
NEW YORK, Dec. 28, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
Scientific Poster Presentation at 2012 Advances in IBD Conference
NEW YORK, Dec. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans
Scientific Poster Presentation This Week at ACG 2012
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
Scientific Poster Presentations This Week at ACG 2012 and UEG Week
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the company
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational
OXIS International poursuit son déploiement mondial de produits avec le lancement du nouveau sérum anti-vieillissement Prograce(TM).
BEVERLY HILLS, Californie, le 20 juillet 2012 (GLOBE NEWSWIRE) -- La société OXIS International, Inc., (OTCBB:OXIS) (Paris:OXI), a annoncé aujourd’hui une étape majeure
OXIS International Continues Its Global Product Rollout With the Release of Its New Prograce(TM) Anti-Aging Serum
BEVERLY HILLS, Calif., July 19, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc., (OTCBB:OXIS) (Paris:OXI) today announced a major step in the implementation of its global product launch strategy with
OXIS annonce le lancement international des ventes en ligne d'ErgoFlex(TM)
BEVERLY HILLS, Californie, 25 juin 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc. (OTCBB: OXIS) (Paris: OXI) a annoncé aujourd’hui, le lancement commercial international d’ErgoFlex(TM)
OXIS Announces the International Launch of Online Sales for ErgoFlex(TM)
BEVERLY HILLS, Calif., June 25, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc. (OTCBB:OXIS) (Paris:OXI) today announced the international commercial launch of its proprietary, clinically proven, joint
OXIS International s'allie à America's Dermatologist, au Dr Tony Nakhla et à l'un des principaux cabinets de relations publiques pour soutenir son entrée sur le marché des soins de la peau avec la formulation EGT(TM)
BEVERLY HILLS, Californie, 25 avril 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc., numéro un du traitement contre le stress oxydatif depuis 1966 (OTCBB:OXIS) (Paris:OXI), a annoncé
OXIS International Joins Forces With "America's Dermatologist," Dr. Tony Nakhla and Leading PR Firm to Support Entry Into Skin Care Market With EGT(TM)
BEVERLY HILLS, Calif., April 24, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc., the leader in oxidative stress since 1966 (OTCBB:OXIS) (Paris:OXI), today announced that it has entered into an Agreement